1. Molecular Docking-assisted Protein Chip Screening of Inhibitors for Bcl-2 Family Protein-protein Interaction to Discover Anticancer Agents by Fragment-based Approach
- Author
-
Youngjin Choi, Sungjoon Cho, and Myoung-Schook Yoou
- Subjects
CHIP assay ,Chemistry ,010401 analytical chemistry ,Bcl-2 family ,Biomedical Engineering ,Bioengineering ,02 engineering and technology ,021001 nanoscience & nanotechnology ,01 natural sciences ,Molecular Docking Simulation ,0104 chemical sciences ,Protein–protein interaction ,Cancer drug discovery ,Drug development ,Biochemistry ,Fragment (logic) ,Electrical and Electronic Engineering ,Protein chip ,0210 nano-technology ,Biotechnology - Abstract
For fragment-based cancer drug discovery, we introduced a molecular docking simulation combined with a protein chip assay. Protein chip technology was used to find fragment-hits that had inhibitory activity against Bcl-2 protein from 131 pre-selected fragment chemicals. Molecular docking simulation was performed for the 12 identified fragment-hits to establish the binding mode of these compounds in the Bcl-2 site. Using the molecular docking-assisted protein chip screening system, we derived a virtual compound structure with an important scaffold feature for interaction with the Bcl-2 protein. We then tested the anticancer activity of 26 compounds that were similar to the scaffold structure. The anticancer activity was confirmed by MTT-assay in A549 lung cancer cells. Finally, three chemicals showed dose-dependent inhibitory activity against cancer cell proliferation. We suggest that the present molecular docking-assisted protein chip assay can be used as a platform technology in the fragment-based drug development process to discover inhibitory agents of protein-protein interactions.
- Published
- 2019
- Full Text
- View/download PDF